BlackRock Inc. Trims Position in Zoetis Inc. (NYSE:ZTS)

BlackRock Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 38,148,300 shares of the company’s stock after selling 1,319,845 shares during the period. BlackRock Inc. owned 8.04% of Zoetis worth $7,109,317,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Bank of The West raised its holdings in Zoetis by 7.8% in the 2nd quarter. Bank of The West now owns 25,176 shares of the company’s stock valued at $4,692,000 after buying an additional 1,831 shares during the period. Grace Capital raised its holdings in Zoetis by 42.0% in the 2nd quarter. Grace Capital now owns 710 shares of the company’s stock valued at $132,000 after buying an additional 210 shares during the period. Deutsche Bank AG raised its holdings in Zoetis by 5.6% in the 2nd quarter. Deutsche Bank AG now owns 1,742,335 shares of the company’s stock valued at $324,702,000 after buying an additional 91,852 shares during the period. NorthCoast Asset Management LLC raised its holdings in Zoetis by 8.0% in the 2nd quarter. NorthCoast Asset Management LLC now owns 28,290 shares of the company’s stock valued at $5,274,000 after buying an additional 2,088 shares during the period. Finally, Hayden Royal LLC raised its holdings in Zoetis by 4.1% in the 2nd quarter. Hayden Royal LLC now owns 1,751 shares of the company’s stock valued at $326,000 after buying an additional 69 shares during the period. Institutional investors and hedge funds own 89.53% of the company’s stock.

In related news, Director Willie M. Reed sold 1,450 shares of the stock in a transaction on Monday, August 23rd. The stock was sold at an average price of $207.10, for a total transaction of $300,295.00. Following the sale, the director now owns 5,964 shares of the company’s stock, valued at $1,235,144.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kristin C. Peck sold 14,500 shares of the stock in a transaction dated Wednesday, August 25th. The stock was sold at an average price of $203.55, for a total value of $2,951,475.00. Following the transaction, the chief executive officer now owns 43,424 shares in the company, valued at $8,838,955.20. The disclosure for this sale can be found here. Insiders sold 48,003 shares of company stock worth $9,711,854 in the last three months. 0.17% of the stock is owned by corporate insiders.

ZTS has been the topic of several research analyst reports. Credit Suisse Group boosted their price objective on shares of Zoetis from $206.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, August 9th. Argus lifted their target price on Zoetis from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, August 25th. Cantor Fitzgerald upped their price target on Zoetis from $210.00 to $238.00 and gave the company an “overweight” rating in a report on Tuesday, July 13th. Raymond James downgraded Zoetis from an “outperform” rating to a “market perform” rating in a report on Friday, July 16th. Finally, Barclays boosted their price objective on Zoetis from $208.00 to $235.00 and gave the company an “overweight” rating in a research note on Friday, August 6th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus price target of $199.08.

ZTS stock traded up $1.04 on Monday, reaching $199.53. 31,243 shares of the company’s stock were exchanged, compared to its average volume of 1,800,599. The stock has a fifty day moving average of $203.34 and a 200-day moving average of $182.16. Zoetis Inc. has a twelve month low of $141.41 and a twelve month high of $210.10. The firm has a market cap of $94.57 billion, a PE ratio of 49.75, a P/E/G ratio of 3.31 and a beta of 0.64. The company has a quick ratio of 2.51, a current ratio of 3.37 and a debt-to-equity ratio of 1.51.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 5th. The company reported $1.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.11. Zoetis had a return on equity of 53.87% and a net margin of 25.76%. During the same period last year, the business earned $0.89 EPS. On average, equities research analysts predict that Zoetis Inc. will post 4.53 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Recommended Story: Stock Portfolio Tracker

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.